Get the Stockscreener App
1.30
2.26%
-0.03
After Hours:
1.29
-0.01
-0.77%
Telomir Pharmaceuticals Inc stock is traded at $1.30, with a volume of 286.26K.
It is down -2.26% in the last 24 hours and down -12.75% over the past month.
Telomir Pharmaceuticals Inc is a pioneering preclinical-stage pharmaceutical company which leads the advancement of age-reversal science. The Company is focused on developing Telomir-1, a novel small molecule designed to lengthen and protect telomeres-the protective DNA end caps of chromosomes that are crucial to cellular aging. As humans and animals age, telomeres naturally shorten, with metal reactivity accelerating this process, increasing the risk of degenerative and age-related diseases. By addressing the underlying causes of aging at the cellular level, Telomir aims to tackle the root of these conditions rather than simply treating their symptoms. Telomir is conducting ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and others.
See More
Previous Close:
$1.33
Open:
$1.33
24h Volume:
286.26K
Relative Volume:
0.07
Market Cap:
$41.97M
Revenue:
-
Net Income/Loss:
$-16.14M
P/E Ratio:
-2.4074
EPS:
-0.54
Net Cash Flow:
$-3.99M
1W Performance:
-4.41%
1M Performance:
-12.75%
6M Performance:
-71.62%
1Y Performance:
-78.30%
1-Day Range:
$1.30
$1.34
1-Week Range:
$1.22
$1.41
52-Week Range:
$1.12
$8.40
Telomir Pharmaceuticals Inc Stock (TELO) Company Profile
Name
Telomir Pharmaceuticals Inc
Sector
Industry
Phone
786-396-6723
Address
100 SE 2ND ST, MIAMI
Compare TELO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TELO
Telomir Pharmaceuticals Inc
|
1.30 | 45.00M | 0 | -16.14M | -3.99M | -0.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.36 | 100.82B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
461.24 | 60.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.06 | 60.69B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
752.32 | 46.32B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
327.20 | 36.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Telomir Pharmaceuticals Inc Stock (TELO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-21-25 | Initiated | Rodman & Renshaw | Buy |
Telomir Pharmaceuticals Inc Stock (TELO) Latest News
Predicting Telomir Pharmaceuticals Inc. trend using moving averages2025 Momentum Check & Reliable Intraday Trade Plans - newser.com
Exit strategy if you’re trapped in Telomir Pharmaceuticals Inc.Trade Entry Summary & Weekly Setup with ROI Potential - newser.com
Options Flow: Is Telomir Pharmaceuticals Inc stock a buy or sellWeekly Trend Recap & AI Forecasted Entry/Exit Points - خودرو بانک
Stock Report: Is Ruanyun Edai Technology Inc.’s growth already priced inMarket Sentiment Summary & AI Enhanced Trading Signals - خودرو بانک
Analyzing recovery setups for Telomir Pharmaceuticals Inc. investorsMarket Growth Report & Community Consensus Picks - newser.com
Aug Sentiment: Is Telomir Pharmaceuticals Inc stock forming a cup and handle2025 Momentum Check & Reliable Momentum Entry Alerts - خودرو بانک
How to build a custom watchlist for Telomir Pharmaceuticals Inc.Portfolio Gains Summary & Low Risk High Win Rate Picks - newser.com
How moving averages guide Telomir Pharmaceuticals Inc. tradingQuarterly Risk Review & Free Expert Verified Stock Movement Alerts - newser.com
Bearish Setup: Will Telomir Pharmaceuticals Inc outperform small cap indexesJuly 2025 Final Week & Real-Time Stock Movement Alerts - خودرو بانک
Price momentum metrics for Telomir Pharmaceuticals Inc. explainedJuly 2025 Sector Moves & Safe Entry Point Alerts - newser.com
Dow Update: What is the long term forecast for Telomir Pharmaceuticals Inc. stock2025 Key Highlights & AI Powered Market Entry Ideas - خودرو بانک
Telomir Pharmaceuticals Reports In Vitro Data Supporting the Potential of Telomir-1 as a First-in-Class Epigenetic Therapy Influencing DNA Methylation Pathways in Cancer, Aging, and Age-Related Diseases - The Marion Star
Quantitative breakdown of Telomir Pharmaceuticals Inc. recent moveMarket Trend Report & AI Driven Price Forecasts - newser.com
Trading Recap: Is BBSI a defensive stock2025 Stock Rankings & Long Hold Capital Preservation Tips - خودرو بانک
Can momentum traders help lift Telomir Pharmaceuticals Inc.Trade Analysis Report & Expert Verified Stock Movement Alerts - newser.com
Can you recover from losses in Telomir Pharmaceuticals Inc.Earnings Miss & Low Drawdown Trading Techniques - newser.com
Telomir Pharmaceuticals Stock Price, Quotes and Forecasts - Benzinga
What high frequency data says about Telomir Pharmaceuticals Inc.2025 Technical Overview & Free Weekly Watchlist of Top Performers - Newser
Telomir Pharmaceuticals Inc. stock trend outlook and recovery pathJuly 2025 PostEarnings & Long Hold Capital Preservation Tips - Newser
Backtesting results for Telomir Pharmaceuticals Inc. trading strategiesGap Up & Community Consensus Trade Alerts - Newser
Short interest data insights for Telomir Pharmaceuticals Inc.Weekly Profit Report & Fast Moving Market Watchlists - Newser
Analyzing net buyer seller activity in Telomir Pharmaceuticals Inc.Rate Cut & Long-Term Capital Growth Strategies - Newser
Published on: 2025-09-12 05:33:48 - Newser
Earnings visualization tools for Telomir Pharmaceuticals Inc.2025 Support & Resistance & High Conviction Buy Zone Picks - Newser
How high can Telomir Pharmaceuticals Inc. stock goTrade Analysis Summary & Real-Time Price Movement Reports - Newser
Chart based exit strategy for Telomir Pharmaceuticals Inc.Portfolio Return Summary & Low Risk Growth Stock Ideas - Newser
Volume spikes in Telomir Pharmaceuticals Inc. stock – what they meanJuly 2025 Closing Moves & Accurate Technical Buy Alerts - Newser
Telomir Pharmaceuticals Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate CDKN2A, a Master Tumor Suppressor, Outperforming Rapamycin and Chemotherapy - The Florida Times-Union
Telomir’s drug candidate shows promise in reversing cancer gene silencing By Investing.com - Investing.com Australia
Telomir’s drug candidate shows promise in reversing cancer gene silencing - Investing.com
Telomir Pharmaceuticals IncTelomir-1 reverses Cdkn2a gene silencingSEC filing - MarketScreener
Key resistance and support levels for Telomir Pharmaceuticals Inc.2025 Pullback Review & Stock Portfolio Risk Management - Newser
Published on: 2025-09-09 08:39:23 - beatles.ru
Published on: 2025-09-09 02:00:19 - beatles.ru
statistical indicators supporting telomir pharmaceuticals inc.’s strengthQuarterly Earnings Summary & Stepwise Entry/Exit Trade Alerts - Newser
Detecting support and resistance levels for Telomir Pharmaceuticals Inc.Short Setup & Real-Time Market Trend Scan - Newser
Telomir Pharmaceuticals Inc. Shows Early Signs of Technical StrengthMarket Sentiment Review & Weekly Momentum Stock Picks - beatles.ru
How to forecast Telomir Pharmaceuticals Inc. trends using time seriesPortfolio Update Summary & Proven Capital Preservation Methods - Newser
Using Python tools to backtest Telomir Pharmaceuticals Inc. strategiesJuly 2025 Analyst Calls & Expert Approved Momentum Ideas - Newser
Is Telomir Pharmaceuticals Inc. stock entering bullish territory2025 Investor Takeaways & Weekly Chart Analysis and Guides - Newser
Is Telomir Pharmaceuticals Inc. still worth holding after the dipEntry Point & Verified Short-Term Plans - Newser
Will Telomir Pharmaceuticals Inc. stock recover after recent dropQuarterly Market Review & Technical Confirmation Alerts - Newser
Published on: 2025-09-08 04:15:57 - Newser
Telomir Pharmaceuticals Inc Stock (TELO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.77%
1.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):